Tawasul
Mubasher TV
Contact Us Advertising   العربية

Hikma Pharmaceuticals to acquire majority stake in GSK Egypt

Hikma Pharmaceuticals to acquire majority stake in GSK Egypt
GSK Egypt reported net profits of EGP 101.41 million in nine months
Glaxo SmithKline
BIOC
8.75% 26.94 2.26
Hikma Pharmaceuticals
HIK
-6.11% 19.20 -1.25

Cairo – Mubasher: Galxo Group Limited signed a non-binding term sheet with Hikma Pharmaceuticals Plc for the potential sale of its entire stake of 91.2% in Glaxo SmithKline (GSK Egypt).

The acquisition will be implemented by submitting a mandatory tender offer for 100% of the shares of the company, GSK Egypt said in a bourse disclosure on Tuesday.

The deal is still pending the completion of satisfactory due diligence, the signing of definitive and binding legal documents, and obtaining approvals from regulatory authorities.

The transaction will include the pharmaceuticals and consumer healthcare business in Egypt and the pharmaceuticals business in Tunisia.

During the first nine months of 2020, GSK Egypt reported net profits of EGP 101.41 million, up from EGP 67.03 million in the corresponding period a year earlier.